ArticleJournal of clinical microbiology2011
Modifications of commercial toxigenic Clostridium difficile PCR resulting in improved economy and workflow efficiency.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Application of Alternative Nucleic Acid Extraction Protocols to ProGastro SSCS Assay for Detection of Bacterial Enteric Pathogens.Journal of clinical microbiology · 2016Article
- Frozen master mix-based modification of commercial reverse transcriptase PCR for detection of influenza and respiratory syncytial viruses.Journal of clinical microbiology · 2015Article
- Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies.Journal of personalized medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expense inherent to molecular diagnostics may prevent laboratories from utilizing real-time PCR for Clostridium difficile infection. Frozen master mix and overnight aliquot modifications of the BD GeneOhm Cdiff assay failed to impact performance indices compared to the package insert protocol (P ≥ 0.31), provided accurate results, and decreased reagent expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.